207 related articles for article (PubMed ID: 36522480)
1. An integrative approach for exploring the nature of fibroepithelial neoplasms.
Yun J; Heo W; Lee ES; Na D; Kang W; Kang J; Chae J; Lee D; Lee W; Hwang J; Yoo TK; Hong BS; Son HY; Noh DY; Lee C; Moon HG; Kim JI
Br J Cancer; 2023 Feb; 128(4):626-637. PubMed ID: 36522480
[TBL] [Abstract][Full Text] [Related]
2. An approach to malignant mammary phyllodes tumors detection.
Ilić I; Randelović P; Ilić R; Katić V; Milentijević M; Velicković L; Krstić M
Vojnosanit Pregl; 2009 Apr; 66(4):277-82. PubMed ID: 19441158
[TBL] [Abstract][Full Text] [Related]
3. Organoid models derived from patients with malignant phyllodes tumor of the breast.
Chu X; Wu M; Yang J; Fu Y; Wang X; Wang H; Xiao Y; Chen D; He J
Breast Cancer Res Treat; 2023 Jul; 200(2):193-201. PubMed ID: 37204665
[TBL] [Abstract][Full Text] [Related]
4. Fibroepithelial lesions; The WHO spectrum.
Krings G; Bean GR; Chen YY
Semin Diagn Pathol; 2017 Sep; 34(5):438-452. PubMed ID: 28688536
[TBL] [Abstract][Full Text] [Related]
5. Phosphohistone H3 expression correlates with manual mitotic counts and aids in identification of "hot spots" in fibroepithelial tumors of the breast.
Ginter PS; Shin SJ; Liu Y; Chen Z; D'Alfonso TM
Hum Pathol; 2016 Mar; 49():90-8. PubMed ID: 26826415
[TBL] [Abstract][Full Text] [Related]
6. Fibroepithelial tumours of the breast-a review.
Lerwill MF; Lee AHS; Tan PH
Virchows Arch; 2022 Jan; 480(1):45-63. PubMed ID: 34505197
[TBL] [Abstract][Full Text] [Related]
7. Core needle biopsy diagnosis of fibroepithelial lesions of the breast: a diagnostic challenge.
Li JJX; Tse GM
Pathology; 2020 Oct; 52(6):627-634. PubMed ID: 32771211
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathologic observation of carcinomas arising in fibroepithelial neoplasms of the breast].
Yang G; Guo L; Jin H; Li J; Ding H
Zhonghua Bing Li Xue Za Zhi; 2014 Jul; 43(7):437-41. PubMed ID: 25327790
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor.
Ng DYX; Li Z; Lee E; Kok JST; Lee JY; Koh J; Ng CC; Lim AH; Liu W; Ng SR; Lim KS; Huang XX; Hong JH; Guan P; Sim Y; Thike AA; Nasir NDM; Li S; Tan PH; Teh BT; Chan JY
NPJ Breast Cancer; 2022 Apr; 8(1):44. PubMed ID: 35365682
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genes.
Kadivar A; Kamalidehghan B; Akbari Javar H; Karimi B; Sedghi R; Noordin MI
Drug Des Devel Ther; 2017; 11():469-481. PubMed ID: 28260860
[TBL] [Abstract][Full Text] [Related]
11. CD146 promotes malignant progression of breast phyllodes tumor through suppressing DCBLD2 degradation and activating the AKT pathway.
Chen J; Xu Q; Liu D; Li X; Guo M; Chen X; Liao J; Lei R; Li W; Huang H; Saw PE; Song E; Yan X; Nie Y
Cancer Commun (Lond); 2023 Nov; 43(11):1244-1266. PubMed ID: 37856423
[TBL] [Abstract][Full Text] [Related]
12. Fibroepithelial lesions revisited: implications for diagnosis and management.
Tan PH
Mod Pathol; 2021 Jan; 34(Suppl 1):15-37. PubMed ID: 32461622
[TBL] [Abstract][Full Text] [Related]
13. Breast sarcomas and malignant phyllodes tumours: comparison of clinicopathological features, treatment strategies, prognostic factors and outcomes.
Lim SZ; Selvarajan S; Thike AA; Nasir ND; Tan BK; Ong KW; Tan PH
Breast Cancer Res Treat; 2016 Sep; 159(2):229-44. PubMed ID: 27541020
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
[TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of a non-gestational choriocarcinoma patient-derived xenograft model.
Oda Y; Niimi K; Yoshida K; Tamauchi S; Yokoi A; Yasui Y; Nishiko Y; Shibata M; Shimizu Y; Yoshihara M; Ikeda Y; Yoshikawa N; Nishino K; Yamamoto E; Kajiyama H
BMC Cancer; 2023 Nov; 23(1):1103. PubMed ID: 37957624
[TBL] [Abstract][Full Text] [Related]
16. Precise diagnosis of breast phyllodes tumors using Raman spectroscopy: Biochemical fingerprint, tumor metabolism and possible mechanism.
Wu Y; Wang Y; He C; Wang Y; Ma J; Lin Y; Zhou L; Xu S; Ye Y; Yin W; Ye J; Lu J
Anal Chim Acta; 2023 Dec; 1283():341897. PubMed ID: 37977771
[TBL] [Abstract][Full Text] [Related]
17. Fibroepithelial lesions of the breast: A review of recurring diagnostic issues.
Seow DYB; Tay TKY; Tan PH
Semin Diagn Pathol; 2022 Sep; 39(5):333-343. PubMed ID: 35523613
[TBL] [Abstract][Full Text] [Related]
18. Malignant phyllodes tumor of the breast: a systematic review.
Lissidini G; Mulè A; Santoro A; Papa G; Nicosia L; Cassano E; Ashoor AA; Veronesi P; Pantanowitz L; Hornick JL; Rossi ED
Pathologica; 2022 Apr; 114(2):111-120. PubMed ID: 35414723
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive genomic profiling of malignant phyllodes tumors of the breast.
Nozad S; Sheehan CE; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon S; Schrock AB; Hirshfield KM; Ali N; Ganesan S; Ali SM; Miller VA; Stephens PJ; Ross JS; Chung JH
Breast Cancer Res Treat; 2017 Apr; 162(3):597-602. PubMed ID: 28210881
[TBL] [Abstract][Full Text] [Related]
20. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
